Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for painful hand and foot psoriasis

NCT ID NCT03135548

Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called spesolimab in 59 people with palmoplantar pustulosis (PPP), a painful skin condition causing pustules and plaques on the palms and soles. Participants received either low or high doses of spesolimab or a placebo for 12 weeks. The goal was to see if the drug could reduce skin symptoms and check for side effects. Results suggest spesolimab may help improve PPP symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Spesolimab
What this could lead to
If successful, this could lead to a new treatment option for palmoplantar pustulosis, reducing painful pustules and plaques on hands and feet.
What could go wrong
This is an early Phase 2 trial with only 59 participants. The drug may not work for everyone, and side effects are possible. More research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

59 people

The number who actually took part.

Started

May 2017

Finished

Nov 2018

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients, 18 to 65 years of age at screening. * Palmoplantar Pustulosis * Further inclusion criteria apply Exclusion Criteria: * Presence or known history of anti- Tumor necrosis factor (TNF)-induced Palmoplantar Pustulosis (PPP)-like disease. * Active or latent tuberculosis * Further exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Palmoplantar pustulosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Aarhus University Hospital, Skejby

    Aarhus, 8200, Denmark

  • Bispebjerg og Frederiksberg Hospital

    København NV, 2400, Denmark

  • Charité - Universitätsmedizin Berlin

    Berlin, 10117, Germany

  • Dr. Irina Turchin PC Inc.

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Gentofte Hospital

    Hellerup, 2900, Denmark

  • Hospital Ramón y Cajal

    Madrid, 28034, Spain

  • Hospital Santa Creu i Sant Pau

    Barcelona, 08026, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, 28031, Spain

  • Innovaderm Research Inc.

    Montreal, Quebec, H2K 4L5, Canada

  • Karolinska Univ. sjukhuset

    Stockholm, 171 76, Sweden

  • Ospedale San Giovanni di Dio

    Cagliari, 09124, Italy

  • Pol. Universitario Tor Vergata

    Roma, 00133, Italy

  • Sahlgrenska US, Göteborg

    Gothenburg, 413 45, Sweden

  • TFS Trial Form Support GmbH

    Hamburg, 20537, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, 60596, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, 69120, Germany

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel

    Kiel, 24105, Germany

  • York Dermatology Clinic and Research Centre

    Richmond Hill, Ontario, L4C 9M7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.